These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 5304771)

  • 21. [Histological characteristics of tuberculous cavity treated with rifampicin--a comparative study with cases treated by primary drugs (author's transl)].
    Tanaka I; Iwai K
    Kekkaku; 1981 Jul; 56(7):355-60. PubMed ID: 7328996
    [No Abstract]   [Full Text] [Related]  

  • 22. [The therapeutic action of Rifampicin, a derivative of 3-(4-methyl-1-piperazinyl-iminomethyl)-rifamycin SV, in pulmonary tuberculosis].
    Lucchesi M; Pallotta G; Rossi P; Sbampato M
    Ann Ist Carlo Forlanini; 1967; 27(3):199-227. PubMed ID: 5602885
    [No Abstract]   [Full Text] [Related]  

  • 23. [Activity of rifampicin in the treatment of pulmonary tuberculosis].
    Nitti V
    Arch Tisiol Mal Appar Respir; 1969 Jun; 24(6):453-93. PubMed ID: 5315095
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection.
    Haley CA; Stephan S; Vossel LF; Sherfy EA; Laserson KF; Kainer MA
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rifampicin-induced renal toxicity during retreatment of patients with pulmonary tuberculosis.
    Rekha VV; Santha T; Jawahar MS
    J Assoc Physicians India; 2005 Sep; 53():811-3. PubMed ID: 16334628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic effects of treatment with RFP on previously treated cases of pulmonary tuberculosis (author's transl)].
    Sakurai H; Watanabe Y; Yamanaka M; Moriguchi T; Fujii K; Uenoyama T
    Kekkaku; 1980 Nov; 55(11):485-91. PubMed ID: 6780716
    [No Abstract]   [Full Text] [Related]  

  • 27. [Humoral and bacteriological findings in patients with pulmonary tuberculosis during rifampicin therapy].
    Stringa C
    G Ital Mal Torace; 1969; ():Suppl 2:107-8. PubMed ID: 5357133
    [No Abstract]   [Full Text] [Related]  

  • 28. [Rifampicin in pulmonary tuberculosis: clinico-radiologic and humoral findings].
    Scarpazza G; Garimoldi M; Cirianni C; Perna G
    G Ital Mal Torace; 1968; 22(5):255-61. PubMed ID: 5704058
    [No Abstract]   [Full Text] [Related]  

  • 29. [Possibilities and limitations of long-term treatment with rifampicin infusion in tubercular disease].
    Rosetti L; Serra A; Arba GV
    G Ital Chemioter; 1982; 29(2):125-32. PubMed ID: 7186465
    [No Abstract]   [Full Text] [Related]  

  • 30. [Studies on short-course chemotherapy of tuberculosis. II. Liver function during 6-month chemotherapy of tuberculosis with hydrazide, rifampicin and pyrazinamide].
    Nikodemowicz E; Kamińska M; Caban M; Struzik T
    Pneumonol Pol; 1984 Oct; 52(10):503-12. PubMed ID: 6533580
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical and radiological results of rifampicin therapy in chronic pulmonary tuberculosis].
    Merenda P
    G Ital Mal Torace; 1969; ():Suppl 2:105-6. PubMed ID: 5357132
    [No Abstract]   [Full Text] [Related]  

  • 32. [Therapeutic effect of Rifampicin on re-treatment cases of pulmonary tuberculosis].
    Kekkaku; 1970 Jul; 45(7):227-35. PubMed ID: 5449510
    [No Abstract]   [Full Text] [Related]  

  • 33. [Preliminary results of treatment of pulmonary tuberculosis with rifampicin].
    Pozzi G; Ferraro S
    G Ital Mal Torace; 1969; ():Suppl 2:17-31. PubMed ID: 5357135
    [No Abstract]   [Full Text] [Related]  

  • 34. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
    Diacon AH; Patientia RF; Venter A; van Helden PD; Smith PJ; McIlleron H; Maritz JS; Donald PR
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2994-6. PubMed ID: 17517849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacodynamics of rifampicin--function of marcrophages].
    Shima K
    Kekkaku; 1979 Dec; 54(12):580-2. PubMed ID: 522355
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical use of rifampicin (R-AMP) in chronic pulmonary tuberculosis].
    Casalone G; Giura R; Lusco G
    G Ital Mal Torace; 1968; 22(4):215-8. PubMed ID: 5743003
    [No Abstract]   [Full Text] [Related]  

  • 37. [Relation between the efficacy of complex therapy of patients with destructive pulmonary tuberculosis and the duration of rifampicin administration].
    Sagalovich VIa; Manzhikova SR
    Probl Tuberk; 1984 Oct; (10):51-4. PubMed ID: 6514699
    [No Abstract]   [Full Text] [Related]  

  • 38. Adrenal function during tuberculous infection and effects of antituberculosis treatment on endogenous and exogenous steroids.
    Keven K; Uysal AR; Erdogan G
    Int J Tuberc Lung Dis; 1998 May; 2(5):419-24. PubMed ID: 9613639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The oral use of rifampicin in 10 cases of chronic pulmonary tuberculosis].
    Soregaroli E; Pozzi M
    G Ital Mal Torace; 1969; ():Suppl 2:14-6. PubMed ID: 5357134
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rifampicin and ethambutol treatment experience in chronic destructive pulmonary tuberculosis].
    Petrova GN; Sedunova EA; Korotaeva TA
    Probl Tuberk; 1981 Mar; (3):73-4. PubMed ID: 7232397
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.